Current oncology最新文献

{"title":"Self-Management Support for Cancer Survivors: A Descriptive Evaluation of the Symptom Navi Training from the Perspective of Health Care Professionals.","authors":"Marika Bana, Selma Riedo, Karin Ribi","doi":"10.3390/curroncol32060326","DOIUrl":"10.3390/curroncol32060326","url":null,"abstract":"<p><p>The Symptom Navi Program (SNP) is a self-management support (SMS) intervention for people with cancer. It consists of self-management supportive leaflets, educational conversations, and two standardized training sessions. A descriptive quality evaluation method was used to evaluate SNP implementation across 14 cancer services from 2021 to 2024. We evaluated training content, methods, and participants' confidence to use SMS in their clinical routine. Nurses, social workers, and psychologists completed ad hoc closed and open-ended questions after each training. The Work Sense of Coherence (Work-SoC) scale was used to elicit participants' self-reported perceptions of their work context at cancer services. A series of descriptive analyses were conducted on the Work-SoC scale, the training content, and the methods. In addition, training-specific questions and predefined hypotheses were correlated. Thematic analysis was employed to examine open-ended questions. The SNP training content and methods largely met participants' needs. Participants' confidence in applying educational conversations decreased over time. The findings suggest a robust correlation between the application of educational conversations in daily routines and the participants' perceptions regarding the comprehensibility and manageability of their work situations. Future research focusing on the implementation of SMS in clinical practice should examine the work context.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.","authors":"Kaili Jin, Xianlei Lin, Xiaoting Xia, Huiling Ye, Dan Yang, Ying Fan, Qiuhua Sun, Rongyun Wang","doi":"10.3390/curroncol32060325","DOIUrl":"10.3390/curroncol32060325","url":null,"abstract":"<p><strong>Background: </strong>Platinum-based chemotherapy significantly increases the risk of nausea and vomiting, which can impair the treatment's efficacy and the patient's quality of life. This meta-analysis examines the incidence and risk factors of platinum-based chemotherapy-induced nausea and vomiting (PINV) in patients treated with this chemotherapy.</p><p><strong>Methods: </strong>This systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. We conducted a literature search in the databases PubMed, Embase, Web of Science, WanFang, China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), and Chinese Medical Association Journal Database (CMAJD) through to 20 January 2025. Studies that reported the incidence and identified risk factors of nausea and vomiting specifically in patients receiving platinum-based chemotherapy were included in the review. The data were extracted independently by two reviewers. The odds ratios (ORs) for each risk factor were calculated from the included studies. Sensitivity analyses and additional subgroup analyses were performed to ensure the robustness of our findings.</p><p><strong>Results: </strong>This meta-analysis included 32 studies involving 14,207 participants. Female sex (OR = 2.363, 95% CI = 1.363-4.096, <i>p</i> = 0.002), anxiety (OR = 1.689, 95% CI = 1.057-2.700, <i>p</i> = 0.028), fatigue (OR = 1.413, 95% CI = 1.145-1.744, <i>p</i> = 0.001), motion sickness (OR = 1.816, 95% CI = 1.266-2.605, <i>p</i> = 0.001), and a history of vomiting during chemotherapy (OR = 2.728, 95% CI = 1.468-5.069, <i>p</i> = 0.002) were significantly associated with an increased risk of PINV.</p><p><strong>Conclusion: </strong>Female sex, anxiety, fatigue, motion sickness, and a history of vomiting during chemotherapy increase the risk of PINV during platinum-based treatments.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Incidence Trend of Early-Onset Obesity-Related and Non-Obesity-Related Cancers.","authors":"Miyu Terashima, Kota Nakayama, Satoko Ugai, Hwa-Young Lee, Yuta Tsukumo, Etsuji Suzuki, Hiroki Mizuno, Minkyo Song, Naoko Sasamoto, Ichiro Kawachi, Tomotaka Ugai","doi":"10.3390/curroncol32060324","DOIUrl":"10.3390/curroncol32060324","url":null,"abstract":"<p><p>The global rise in obesity prevalence and the incidence of early-onset cancer (diagnosed between 20 and 49 years of age) is a serious public health concern. We, therefore, evaluated the recent global trends in the incidence of early-onset obesity-related cancers and compared them to those of non-obesity-related cancers. We obtained age-standardized incidence rates of early-onset cancers diagnosed between 2000 and 2012 in 44 countries from the Cancer Incidence in Five Continents database. Using joinpoint regression models, we calculated the average annual percentage changes (AAPCs) and their corresponding 95% confidence intervals (95% CIs) for combined and individual categories of obesity-related cancers (11 and 9 cancer types in females and males, respectively) and non-obesity-related cancers (12 cancer types in both females and males). Differences in the AAPC were assessed by comparing 95% CIs, where nonoverlapping 95% CIs were considered statistically significantly different. We observed statistically significant positive AAPCs for early-onset obesity-related cancers in all available countries combined among females (global AAPC, 4.3%; 95% CI, 4.1-4.6%) and males (global AAPC, 1.4%; 95% CI, 1.2-1.7%). When analyzed by countries, we observed statistically significant positive AAPCs in 26 countries among females and 11 countries among males. AAPCs for early-onset obesity-related cancers were statistically significantly higher than those of non-obesity-related cancers in several regions, especially North America and Oceania. In conclusion, this study indicates that the incidence of early-onset obesity-related cancers exhibited a more pronounced increasing trend than non-obesity-related cancers among both sexes in many countries and regions.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Clinical-Radiomics Nomogram for the Preoperative Prediction of Aggressive Micropapillary and a Solid Pattern in Lung Adenocarcinoma.","authors":"Xiangyu Xie, Lei Chen, Kun Li, Liang Shi, Lei Zhang, Liang Zheng","doi":"10.3390/curroncol32060323","DOIUrl":"10.3390/curroncol32060323","url":null,"abstract":"<p><p><b>Background:</b> A micropapillary pattern (MP) and solid pattern (SP) in lung adenocarcinoma (LUAD), a major subtype of non-small-cell lung cancer (NSCLC), are associated with a poor prognosis and necessitate accurate preoperative identification. This study aimed to develop and validate a predictive model combining clinical and radiomics features for differentiating a high-risk MP/SP in LUAD. <b>Methods:</b> This retrospective study analyzed 180 surgically confirmed NSCLC patients (Stages I-IIIA), randomly divided into training (70%, n = 126) and validation (30%, n = 54) cohorts. Three prediction models were constructed: (1) a clinical model based on independent clinical and CT morphological features (e.g., nodule size, lobulation, spiculation, pleural indentation, and vascular abnormalities), (2) a radiomics model utilizing LASSO-selected features extracted using 3D Slicer, and (3) a comprehensive model integrating both clinical and radiomics data. <b>Results:</b> The clinical model yielded AUCs of 0.7975 (training) and 0.8462 (validation). The radiomics model showed superior performance with AUCs of 0.8896 and 0.8901, respectively. The comprehensive model achieved the highest diagnostic accuracy, with training and validation AUCs of 0.9186 and 0.9396, respectively (DeLong test, <i>p</i> < 0.05). Decision curve analysis demonstrated the enhanced clinical utility of the combined approach. <b>Conclusions:</b> Integrating clinical and radiomics features significantly improves the preoperative identification of aggressive NSCLC patterns. The comprehensive model offers a promising tool for guiding surgical and adjuvant therapy decisions.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Necessity and Reconstruction Methods of Splenic Vein After Resection of the Portomesenteric Junction During Resections for Pancreatic Cancer.","authors":"Moath Alarabiyat, Nikolaos Chatzizacharias","doi":"10.3390/curroncol32060316","DOIUrl":"10.3390/curroncol32060316","url":null,"abstract":"<p><p>Pancreatic cancer involving the porto-mesenteric junction (PMJ) represents a challenge to pancreatic surgeons. Restoring mesenteric venous drainage is an essential component of vascular reconstruction after tumour resection. In contrast, management of the splenic venous drainage can involve the ligation or reconstruction of the splenic vein (SV). Evidence suggests that splenic vein ligation (SVL) is commonly associated with sinistral portal hypertension (SPH), especially if multiple venous tributaries were divided to facilitate resection. Although the association between SVL and SPH is well documented, the risk of symptomatic SPH is not widely reported, presumably due to the low incidence and poor survival of pancreatic cancer patients. Splenic vein reconstruction (SVR) has been proposed to decrease the risk of SPH but is fraught with technical complexity and increased morbidity. Moreover, SVR does not guarantee the prevention of SPH, as patency rates vary and associated hemodynamic changes are unpredictable. Patient selection and the surgical expertise available can guide SV intraoperative management, taking into consideration the risks and benefits associated with each approach. A comprehensive review of the current literature highlighting the incidence and clinical impact of SPH after the resection of pancreatic cancer involving the PMJ is presented.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Design of a Patient-Centered Hierarchal Composite Outcome for a Multi-Center Randomized Controlled Trial in Metastatic Bone Disease.","authors":"Hadia Farrukh, Abbey Kunzli, Olivia Virag, Nathan O'Hara, Sheila Sprague, Amy Cizik, Ricardo Gehrke-Becker, Thomas Schubert, Michelle Ghert","doi":"10.3390/curroncol32060318","DOIUrl":"10.3390/curroncol32060318","url":null,"abstract":"<p><p>The proximal femur represents the most frequent site in the appendicular skeleton for metastatic bone disease (MBD) to occur, with a high risk for pathologic fracture. While surgical stabilization is typically used to manage fractures, reconstruction approaches are gaining popularity due to improved survival. Previous studies have focused on clinical outcomes, but patient-centered outcomes remain underexplored. This study aims to develop a patient-centered primary outcome for the Proximal FEmur Reconstruction or Internal Fixation fOR Metastases (PERFORM) Randomized Controlled Trial, employing a mixed-methods approach. First, a focus group with advanced cancer patients and caregivers identified relevant outcomes. Next, a discrete choice experiment (DCE) assessed the importance of these outcomes among stakeholders, including surgeons, patients and caregivers. The most important components for the primary outcome were identified: mortality within twelve months, physical function assessed at four months using the PROMIS^® Global Physical Function score, and the number of days at home within twelve months. The DCE further confirmed that survival and physical function were most prioritized. The PERFORM trial's primary outcome, developed through extensive stakeholder engagement, will guide the evaluation of surgical approaches for MBD of the proximal femur and has the potential to influence patient-centered practice.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).","authors":"Tobias Berg, Brittany Salter, Michael Radford, He Tian Tony Chen, Brian Leber","doi":"10.3390/curroncol32060319","DOIUrl":"10.3390/curroncol32060319","url":null,"abstract":"<p><p>Allogeneic hematopoietic cell transplantation (alloHCT) is the sole curative therapy for myelodysplastic syndrome (MDS). While alloHCT clearly confers a significant survival advantage in high-risk MDS, it is less clear how the disease burden and impact of conditioning intensity impact survival. This review addresses critical issues surrounding this topic, emphasizing the unique cell biology of MDS and the evolving concepts of conditioning intensity compared to other diseases, including acute myeloid leukemia (AML). The review is structured around three interconnected themes. First, it clarifies the varying interpretations of conditioning intensity. Second, it examines the interplay between disease burden at transplant and conditioning intensity in determining outcomes, including a comparative analysis with acute myeloid leukemia (AML) to highlight similarities and differences. Third, it explores the relationship between conditioning regimen intensity and immune reconstitution, particularly focusing on the graft-versus-tumor (GvT) effect and its potential modulation by conditioning intensity. Understanding the stem cell target of conditioning regimens is emphasized, as the persistence of the underlying MDS stem cell necessitates a thorough understanding of this concept for improved therapeutic strategies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?","authors":"Pilar Lloret-Madrid, Pedro Chorão, Manuel Guerreiro, Pau Montesinos","doi":"10.3390/curroncol32060322","DOIUrl":"10.3390/curroncol32060322","url":null,"abstract":"<p><p><b>Background</b>: Patients with refractory and relapsed acute myeloid leukemia (R/R AML) face a dismal prognosis. CAR-T therapy has emerged as a potential treatment option. This study assesses the available clinical evidence on CAR-T in R/R AML, focusing on safety and efficacy outcomes. <b>Methods</b>: We included studies on CAR-T therapy for R/R AML published from June 2014 to January 2025. Data on patient and disease characteristics, CAR-T constructs, response rates, post-CAR-T allogeneic HSCT (allo-HSCT), and safety outcomes were analyzed. <b>Results</b>: Twenty-five CAR-T clinical trials involving 296 patients were identified. The most frequently targeted antigens were CD33, CD123, and CLL-1, while CD7, CD19, NKG2D, and CD38 were also explored. Responses were heterogeneous and often short-lived when not consolidated with allo-HSCT. Cytokine release syndrome and neurotoxicity were generally low grade and manageable. Prolonged and severe myelosuppression was a frequent limiting toxicity, often requiring allo-HSCT to restore hematopoiesis. Disease progression was the leading cause of death, followed by infections. <b>Conclusions</b>: CAR-T cell therapy may represent a feasible therapeutic strategy, particularly as bridging to allo-HSCT to mitigate myelotoxicity and improve long-term outcomes. Nevertheless, it remains in the early stages of development and faces significant efficacy and safety challenges that must be addressed in future trials to enable the expansion of this promising therapeutic approach for a population with high unmet medical needs.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Management of Extra-Abdominal Desmoid Fibromatosis: A Retrospective Analysis of Treatments, Outcomes and Recurrence Patterns.","authors":"Vidhi Saraf, Hariharan Triplicane Dwarakanathan, Al-Muaayad Al-Abri, Ioanna Nixon, Sarah Vaughan, Ashish Mahendra, Sanjay Gupta","doi":"10.3390/curroncol32060320","DOIUrl":"10.3390/curroncol32060320","url":null,"abstract":"<p><p><b>Background:</b> Desmoid fibromatosis (DF) is a rare, locally aggressive soft tissue tumour with unpredictable clinical behaviour. Historically, treatment has involved surgery; however, contemporary guidelines, such as those from the Desmoid Tumour Working Group, advocate active surveillance. This article reviews current perspectives on DF, focusing on epidemiology, pathogenesis, treatment strategies, emerging research directions and cost effectiveness based on our experience at the West of Scotland Musculoskeletal Oncology Service, Glasgow Royal Infirmary (GRI). <b>Methodology:</b> We reviewed 101 patients diagnosed with desmoid fibromatosis between 2010 and 2024. A review of patient records was conducted to gather information on demographics, date of diagnosis, prior treatment, treatment initiation, intervention types, imaging intervals, follow-up duration, recurrence rate for surgery and other intervention, and discharge timelines. All data was systematically organized and analyzed to assess our outcomes. <b>Results:</b> Out of 101 patients with DF in the study, 66% were females. The most common site of primary tumour was lower extremity (39.6%) followed by near equal distribution in upper extremity and trunk. Out of the total cases, 72 (71.2%) were successfully managed with active surveillance involving serial imaging and clinical reviews in accordance with European guidelines. A total of 22 patients (21%) received treatment: 10 underwent surgery alone, 2 had surgery combined with radiotherapy, 8 received only radiotherapy, 1 was treated with hormonal therapy and 1 participated in a trial with Nirogacestat. Of the seven remaining patients, six had unplanned surgery outside followed by active surveillance at GRI. One patient was on alternative treatment modality, homeopathy. The average number of MRI scans per patient was 3.11, with many patients requiring significantly more imaging. MRI surveillance varies significantly in desmoid tumours due to their heterogeneous behaviour. Active or symptomatic tumours often require more frequent scans (every 3-6 months), while stable cases may need only imaging annually or just clinical monitoring. Recurrence was noted in eight patients, all of which were related to prior surgery. The total combined cost of imaging and appointments exceeds £6500 per patient in active surveillance. <b>Conclusions:</b> We conclude that most patients with desmoid fibromatosis in our cohort were effectively treated with active surveillance, consistent with current European guidelines. Surgical management of desmoid fibromatosis in our cohort is historic and has shown a significant recurrence risk. Our study proposes a revised follow-up protocol that significantly reduces costs without compromising on patient care. We suggest a two-year surveillance period for stable disease with patient-initiated return to reduce unnecessary clinic visits, imaging and healthcare costs.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Deep Learning-Based Auto-Contouring Software Achieve Accurate Pelvic Volume Delineation in Volumetric Image-Guided Radiotherapy for Prostate Cancer? A Preliminary Multicentric Analysis.","authors":"Cristiano Grossi, Fernando Munoz, Ilaria Bonavero, Eulalie Joelle Tondji Ngassam, Elisabetta Garibaldi, Claudia Airaldi, Elena Celia, Daniela Nassisi, Andrea Brignoli, Elisabetta Trino, Lavinia Bianco, Silvia Leardi, Diego Bongiovanni, Chiara Valero, Maria Grazia Ruo Redda","doi":"10.3390/curroncol32060321","DOIUrl":"10.3390/curroncol32060321","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) is a mainstay treatment for prostate cancer (PC). Accurate delineation of organs at risk (OARs) is crucial for optimizing the therapeutic window by minimizing side effects. Manual segmentation is time-consuming and prone to inter-operator variability. This study investigates the performance of Limbus^® Contour^® (LC), a deep learning-based auto-contouring software, in delineating pelvic structures in PC patients.</p><p><strong>Methods: </strong>We evaluated LC's performance on key structures (bowel bag, bladder, rectum, sigmoid colon, and pelvic lymph nodes) in 52 patients. We compared auto-contoured structures with those manually delineated by radiation oncologists using different metrics.</p><p><strong>Results: </strong>LC achieved good agreement for the bladder (median Dice: 0.95) and rectum (median Dice: 0.83). However, limitations were observed for the bowel bag (median Dice: 0.64) and sigmoid colon (median Dice: 0.6), with inclusion of irrelevant structures. While the median Dice for pelvic lymph nodes was acceptable (0.73), the software lacked sub-regional differentiation, limiting its applicability in certain other oncologic settings.</p><p><strong>Conclusions: </strong>LC shows promise for automating OAR delineation in prostate radiotherapy, particularly for the bladder and rectum. Improvements are needed for bowel bag, sigmoid colon, and lymph node sub-regionalization. Further validation with a broader and larger patient cohort is recommended to assess generalizability.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}